-
1 × ₨ 210.00
-
1 × ₨ 720.00
-
1 × ₨ 1,192.00
-
1 × ₨ 227.92
-
1 × ₨ 120.00
-
1 × ₨ 1,600.00
-
1 × ₨ 336.00
-
1 × ₨ 94.02
-
1 × ₨ 130.00
-
1 × ₨ 550.00
-
1 × ₨ 120.00
-
1 × ₨ 53.00
-
1 × ₨ 98.00
-
2 × ₨ 107.00
-
1 × ₨ 56.00
-
1 × ₨ 1,155.00
-
1 × ₨ 90,000.00
-
1 × ₨ 45.00
-
1 × ₨ 20.00
-
1 × ₨ 520.00
-
1 × ₨ 965.00
-
1 × ₨ 225.00
-
1 × ₨ 63.00
-
1 × ₨ 62.50
-
2 × ₨ 400.00
-
1 × ₨ 535.00
-
1 × ₨ 1,172.94
-
1 × ₨ 140.00
-
1 × ₨ 567.00
-
1 × ₨ 1,200.80
-
1 × ₨ 1,500.00
-
1 × ₨ 360.00
-
1 × ₨ 878.04
-
1 × ₨ 161.00
-
1 × ₨ 163.00
-
1 × ₨ 35.43
-
1 × ₨ 720.00
-
1 × ₨ 2,696.00
-
1 × ₨ 302.00
-
1 × ₨ 71.42
-
1 × ₨ 885.00
-
1 × ₨ 120.00
-
1 × ₨ 645.00
-
1 × ₨ 148.00
-
1 × ₨ 1,520.00
Roll over image to zoom in
SITAPIN 50MG
₨ 277.00₨ 308.00 (-10%)
- For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
- Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Reviews
There are no reviews yet.